- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00605345
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.
August 17, 2016 updated by: Hoffmann-La Roche
An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera Versus Darboepoetin Alfa for the Maintenance of Haemoglobin Levels in Renal Transplant Recipients With Chronic Renal Anaemia.
This two arm study will compare the efficacy and safety of subcutaneous Mircera versus darbepoetin alfa for the maintenance of hemoglobin levels in kidney transplant recipients with chronic renal anemia.
Patients currently receiving maintenance treatment with darbepoetin alfa will be randomized either to receive 4-weekly injections of Mircera with a starting dose (120, 200 or 360 micrograms subcutaneously) derived from the dose of darbepoetin alfa they were receiving in the 2 weeks preceding study start, or to stay on 2-weekly darbepoetin alfa therapy.
The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
71
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alicante, Spain, 03010
-
Badajoz, Spain, 06080
-
Barcelona, Spain, 08036
-
Barcelona, Spain, 08003
-
Barcelona, Spain, 08025
-
Ciudad Real, Spain, 13005
-
Granada, Spain, 18014
-
Madrid, Spain, 28040
-
Madrid, Spain, 28041
-
Madrid, Spain, 28007
-
Madrid, Spain, 28222
-
Valencia, Spain, 46017
-
Valladolid, Spain, 47005
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08915
-
Hospitalet de Llobregat, Barcelona, Spain, 08907
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
-
-
Cordoba
-
Córdoba, Cordoba, Spain, 14004
-
-
La Coruña
-
La Coruna, La Coruña, Spain, 15006
-
Santiago de Compostela, La Coruña, Spain, 15706
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spain, 48903
-
Galdakao, Vizcaya, Spain, 48960
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adult patients, > or = 18 years of age;
- kidney transplant recipients with stage 3 or stage 4 chronic kidney disease;
- functioning graft of > 6 months and < 10 years after kidney transplantation, with no signs of acute rejection;
- stable maintenance subcutaneous darbepoetin alfa therapy every 2 weeks.
Exclusion Criteria:
- transfusion of red blood cells during previous 2 months;
- poorly controlled hypertension;
- significant acute or chronic bleeding;
- need for dialysis therapy expected in next 6 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CERA Treatment Once Monthly
|
120, 200 or 360 micrograms sc 4-weekly (starting dose)
|
ACTIVE_COMPARATOR: Darbepoetin Alfa Once Biweekly
|
As prescribed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Percentage of Participants Maintaining Average Haemoglobin (Hb) Concentration During the Efficacy Evaluation Period (EEP) Within the Target Range
Time Frame: Weeks 16-28
|
Key outcomes will be assessed during the first 12 weeks following the 16 weeks dose titration period, i.e. during the Efficacy Evaluation Period (EEP).
Assessments performed every four weeks, beginning at week 16 up to week 28.
The reference haemoglobin is defined as the mean of the two assessments recorded during the SVP (weeks -4 and -2).
For the purposes of efficacy assessment the target haemoglobin concentration range will be defined as ± 1 g/dL of the reference haemoglobin concentration AND within the range 10 - 12 g/dL.
|
Weeks 16-28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Hb Concentration From Baseline to Efficacy Evaluation Period (EEP)
Time Frame: Baseline to 28 weeks
|
Reference haemoglobin at baseline is defined as the mean of the two assessments recorded at weeks -4 and -2.
Additional assessments were then performed every 4 weeks at week 0 through week 28.
Mean change was calculated as value at 28 weeks minus baseline.
|
Baseline to 28 weeks
|
Percentage of Participants Maintaining Hb Concentration in 10-12 g/dL Range Throughout the Efficacy Evaluation Period (EEP)
Time Frame: Weeks 16-28
|
Weeks 16-28
|
|
Mean Time Spent in 10-12g/dL Range During the Efficacy Evaluation Period (EEP)
Time Frame: Weeks 16-28
|
Efficacy Evaluation Period was the 12 weeks following 16 weeks of treatment in the Dose Titration Period.
|
Weeks 16-28
|
Percentage of Participants Needing Dose Adjustments
Time Frame: Up to 28 weeks
|
Assessment of the Dose Titration Period of 16 weeks of treatment and following 12 weeks, known as the Efficacy Evaluation Period (EEP).
|
Up to 28 weeks
|
Incidence of RBC Transfusions
Time Frame: Up to 28 weeks
|
Assessment of the Dose Titration Period of 16 weeks of treatment and following 12 weeks, known as the Efficacy Evaluation Period (EEP).
|
Up to 28 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2007
Primary Completion (ACTUAL)
July 1, 2009
Study Completion (ACTUAL)
July 1, 2009
Study Registration Dates
First Submitted
January 18, 2008
First Submitted That Met QC Criteria
January 18, 2008
First Posted (ESTIMATE)
January 31, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
September 23, 2016
Last Update Submitted That Met QC Criteria
August 17, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ML21058
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on methoxy polyethylene glycol-epoetin beta [Mircera]
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedRenal Insufficiency, Chronic | AnemiaUnited States, Spain, France, Hungary, Italy, Lithuania, Poland
-
Hoffmann-La RocheCompletedAnemiaUnited States, Canada, United Kingdom, Mexico, Poland
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedAnemiaItaly, Spain, United States, Germany
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted